基因敲除
细胞生物学
细胞凋亡
激活剂(遗传学)
程序性细胞死亡
线粒体
生物
基因
生物化学
作者
Zhezhe Qu,Xiaochen Pang,Zhongting Mei,Ying Li,Yaozhi Zhang,Chuanhao Huang,Kuiwu Liu,Shuting Yu,Changhao Wang,Zhiyong Sun,Yingqi Liu,Xin Li,Yingqiong Jia,Yuechao Dong,Meixi Lu,Tiantian Ju,Fan Wu,Min Huang,Na Li,Shunkang Dou
出处
期刊:Redox biology
[Elsevier BV]
日期:2024-04-02
卷期号:72: 103145-103145
被引量:10
标识
DOI:10.1016/j.redox.2024.103145
摘要
Ferroptosis is a nonapoptotic form of regulated cell death that has been reported to play a central role in cardiac ischemia‒reperfusion (I/R) injury. N-acetyltransferase 10 (NAT10) contributes to cardiomyocyte apoptosis by functioning as an RNA ac4c acetyltransferase, but its role in cardiomyocyte ferroptosis during I/R injury has not been determined. This study aimed to elucidate the role of NAT10 in cardiac ferroptosis as well as the underlying mechanism. The mRNA and protein levels of NAT10 were increased in mouse hearts after I/R and in cardiomyocytes that were exposed to hypoxia/reoxygenation. P53 acted as an endogenous activator of NAT10 during I/R in a transcription-dependent manner. Cardiac overexpression of NAT10 caused cardiomyocyte ferroptosis to exacerbate I/R injury, while cardiomyocyte-specific knockout of NAT10 or pharmacological inhibition of NAT10 with Remodelin had the opposite effects. The inhibition of cardiomyocyte ferroptosis by Fer-1 exerted superior cardioprotective effects against the NAT10-induced exacerbation of post-I/R cardiac damage than the inhibition of apoptosis by emricasan. Mechanistically, NAT10 induced the ac4C modification of Mybbp1a, increasing its stability, which in turn activated p53 and subsequently repressed the transcription of the anti-ferroptotic gene SLC7A11. Moreover, knockdown of Mybbp1a partially abolished the detrimental effects of NAT10 overexpression on cardiomyocyte ferroptosis and cardiac I/R injury. Collectively, our study revealed that p53 and NAT10 interdependently cooperate to form a positive feedback loop that promotes cardiomyocyte ferroptosis to exacerbate cardiac I/R injury, suggesting that targeting the NAT10/Mybbp1a/p53 axis may be a novel approach for treating cardiac I/R.
科研通智能强力驱动
Strongly Powered by AbleSci AI